Lidingo

This research aims to evaluate the long-term safety and explore the effectiveness of astegolimab in people with chronic obstructive pulmonary disease (COPD) who have already completed a 52-week treatment in previous studies GB43311 or GB44332. The study focuses on participants aged 40 to 90 years and is a Phase III open-label extension trial designed to continue monitoring patients after their initial treatment period. Participants will receive astegolimab as a subcutaneous injection every two weeks during this extension study. This treatment continues from the prior placebo-controlled phase, allowing researchers to observe any ongoing effects and safety concerns over a longer period. The study does not include a placebo group during this extension phase, and all participants receive the active treatment. Throughout the study, researchers will closely monitor participants for any adverse events up to 12 weeks after the last dose of astegolimab. Participants will be assessed regularly to ensure their safety and to gather data on the treatment's long-term impact. The total duration of participant involvement depends on when they completed the parent studies but involves continued monitoring during and after the treatment period.

Researchers are evaluating how well tofacitinib works and how patients stick to their treatment for ulcerative colitis in real-life clinical settings in Sweden. This observational study uses data from the ongoing National Swedish registry called SWIBREG and also looks at prescription records to understand treatment adherence. The focus is on measuring clinical disease activity and remission rates over time. Participants in the study receive tofacitinib as prescribed by their doctors according to standard clinical practice and official guidelines. The study does not assign treatments but observes patients who have already been prescribed tofacitinib. Data collection includes records from SWIBREG and the Swedish Prescribed Drug Register to monitor treatment use and clinical outcomes. During the study, researchers track participants' disease activity through clinical assessments and laboratory tests, including fecal calprotectin levels and endoscopic scores. The main outcome measured is the proportion of participants in remission after 52 weeks, as indicated by the Partial Mayo Score. Patients provide informed consent, and their data is collected at baseline and throughout the study to assess treatment effectiveness and adherence over time.